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    Diabetes has been a crucial medical and social problem worldwide. For adequate nutritional therapy, there 
have been discussions concerning Calorie Restriction (CR) and Low Carbohydrate Diet (LCD). We have 
investigated glucose variability of diabetic patients applying CR, LCD, continuous glucose monitoring (CGM) and 
applied FreeStyle Libre which is flash glucose monitoring (FGM). The patient is a 40-year-old female with type 2 
diabetes mellitus (T2DM), who showed BMI 20.7, postprandial blood glucose 257 mg/dL. HbA1c 12.1%, 
Glycoalbumin 31.6% (11.6-16.4), serum C-peptide 2.0 ng/ml and unremarkable data of liver function, renal, 
lipids. She was provided the intervention of three stages, which are i) CR with 60% carbohydrate in Day 1-2, ii) 
LCD meal with 12% carbohydrate in Day 3-5; iii) LCD + Sodium-glucose cotransporter 2 (SGLT2) inhibitor 
(Ipragliflozin L-Proline 50mg) in Day 6-12. The glucose profile was measured by FreeStyle Libre Pro (Abbott) for 
14 days. The daily profile of blood glucose was abruptly decreased on Day 6. Time percentage of satisfactory blood 
glucose 70-180 mg/dL (/24h) was 0%, 0%, 2%, 14%, 0%, 54%, 100% in Day 1-7, respectively. These results 
suppose the acute clinical efficacy of SGLT2 inhibitor, and this report would become a reference for future 
diabetic practice and research.  
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Introduction 
    In recent years, diabetes has been an important 
medical and social problem in the world. For adequate 
treatment of Type 1 and Type 2 Diabetes Mellitus 
(T1DM, T2DM), detail blood glucose variability can be 
measured and evaluated. In diabetic practice, 
continuous glucose monitoring (CGM) has been 
introduced and developed for years. CGM system has 
revealed various useful efficacy and influences [1]. 
Furthermore, it shows beneficial self-efficacy and 
other positive attitudes from advanced technology [1]. 
In several reports, it could detect minute glucose 
changes by preventing hypoglycemic episodes and 
other harmful events [2].  
 
    CGM has been prevalent in clinical practice and 
evaluated for a useful method in order to optimize 
glucose variability in diabetes [3]. When the patients 
are in the program of low carbohydrate diet (LCD), 
CGM can become beneficial apparatus for the target of 
glycemic control with professional management [3].  
 
    The fundamental therapy for T1DM and T2DM 
would be nutritional treatment. Historically speaking, 
calorie restriction (CD) (low-fat) meal was formerly 
broadly conducted for usual therapy. However, the 
effect had not been so satisfactory. Successively, 
Bernstein and Atkins presented the new nutritional 
method of LCD. LCD has been prevalent in North 
American and European countries until now [4]. After 
that, many useful results for LCD have been observed 
so far with the beneficial effects of LCD. Among them, 
the report from Dietary Intervention Randomized 
Controlled Trial (DIRECT) Group reported the actual 
efficacy of LCD for 2 years and 4 years with medical 
evidence [5,6]. There have been many reports 
suggesting the predominance of LCD rather than CR 
until now [7-9].  
 
    On the other hand, LCD was initiated in Japan by 
the author and colleagues [10]. After that, our group 
has continued clinical practice and research and 
educational seminars for developing LCD information 
and practice. Furthermore, we have established the 
Japan LCD Promotion Association (JLCDPA) for a 
social movement of adequate anti-aging medicine. 
Among them, we have educated many people on how 
to continue LCD successfully, which is the application 
of three types of LCD. Those are super-LCD, standard-
LCD, and petite LCD, including carbohydrate ratio of 
12%, 26%, 40%, respectively [11]. Our group 
investigators have clarified the physiological beneficial 
role from hyperketonemia in the axis of a pregnant 
mother, newborn, placenta and fetus [12]. 
Furthermore, a comparison of the daily profile of 
glucose variability on CR and LCD has investigated, 
and CR breakfast with 70g of carbohydrate has been 
utilized for meal tolerance test (MTT) similar to 
75gOGTT [13,14].  
 
    For several years, the detail measurement of blood 
glucose variability has been possible. The technology 
has been continuous glucose monitoring (CGM) 
systems in the diabetic practice [15]. After that, flash 
glucose monitoring (FGM) has been introduced with 
higher technology. Thus, the medical apparatus 
FreeStyle Libre Pro has been prevalent bringing easier 
management for analysis of glucose fluctuation [16].  
 
    Our group has continued FGM studies, and we 
experienced a T2DM case with medically interesting 
progress using FGM and sodium-glucose co-
transporter 2 (SGLT2) inhibitors. Then we report the 
case and discuss s in this article.    
 
Case Presentation 
History of Present Illness: 
    The case was a 40 years-old female. She was 
diagnosed as T2DM about 11 years ago. At that time, 
she was pointed out to be diabetic when she received 
an annual check-up. She has a negative family history 
for diabetes or particular diseases. About 4 years ago, 
she revealed a rather higher HbA1c value and has 
treated for T2DM by anti-diabetic oral medicine for a 
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few months. After that, she did not visit the clinic for 
the treatment of T2DM.  
 
    After 3 years follow up the natural course without 
therapy, she was advised to visit diabetologist because 
of elevated HbA1c value. 
 
Clinic Visits and Examination Results: 
    She visited the diabetes department of the clinic. 
Her physicals and vitals were unremarkable. Her 
stature showed 162 cm and 54.5 kg, and her body 
mass index (BMI) was 20.7 kg/m2. 
 
    There are several routine examinations for 
diabetes, including postprandial blood glucose 257 
mg/dL, HbA1c 12.1%, Glycoalbumin 31.6% (11.6-16.4) 
and serum C-peptide 2.0 ng/ml. Two weeks after her 
first contact, she was admitted for detail evaluation 
and treatment of LCD. 
 
General Examination: 
    Urinalysis showed the following results: protein 
negative, sugar strongly positive, urobilinogen 
negative, occult blood negative. Occult blood in stool 
was negative. Chest X-ray and ECG were within 
normal limits. Echograms of the carotid artery, heart 
and abdomen were unremarkable.  
 
Blood Biochemistry: 
    Blood test showed the following: Complete blood 
count (CBC); WBC 4900/μl, RBC 503 x 104/μl, Hb 13.5 
g/dL, CRP 0.03 mg/dL, BUN 16 mg/dL, Cre 0.6 
mg/dL, Uric Acid 6.1 mg/dL, total protein 7.2 g/dL, 
Albumin 4.3 g/dL, AST 19 IU/mL, ALT 20 IU/mL, LDH 
162 IU/mL, r-GTP 17 IU/mL, Triglyceride 101 mg/dL, 
HDL-C 69 mg/dL, LDL-C 173 mg/dL.  
 
Diabetes-related Exams: 
    There are several data about diabetes as follows: i) 
anti-GAD antibody < 0.5 (< 0.5), ii) Urinary sugar 
(g/day) was 47.7g, 17.2, 6.8g and 52.1g/day, in day 
3,4,5,6, respectively. Its normal range is less than 0.15 
g/day. LCD was provided on day 3-14. SGLT2-
inhibitor agent was given in day 6, iii) On day 14, her 
blood glucose was 78 mg/dL in fasting 0700h, and 91 
mg/dL in 2 hours after lunch, iv) Ketone body in blood 
was 3394 μmol/L (< 76) on day 14. 
 
Meals of CR and LCD:  
    She was provided the usual CR meal for days 1 and 
2. After that, she was on LCD from day 3 to day 14. 
The nutritional content of CR has been from the 
nutrient balance of the Japan Diabetes Society (JDS). It 
is standard balance with protein 15%, fat 25% and 
carbohydrate 60% [17]. 
 
    The protocol of LCD was provided from day 3 to 
day 14. The LCD content was 1400 kcal/day, and the 
carbohydrate ratio was 12% [11]. By the calculation, 
carbohydrate intake is 1400 x 0.12 = 168 cal/day by 
the intake of carbohydrates. It equals to 42 g of 
carbohydrate per day. 
 
FGM System: 
    In order to study the detailed blood glucose 
variability, the FGM system was applied. The 
apparatus was FreeStyle Libre Pro, which has been 
introduced to clinical practice [18]. It has been 
produced by Abbott Diabetes Care Inc., Alameda, CA, 
USA [15]. As this apparatus has shown reliable results 
in clinical trials, it has been evaluated as simple and 
beneficial for detecting blood glucose movement 
simultaneously [16]. 
 
    The detail blood variability was studied for 14 days. 
Regarding the evaluation of blood variability, the 
normal range of glucose was considered satisfactory 
range as the level between 70 mg/dL to 180 mg/dL. 
When the blood glucose is within the normal range, a 
satisfactory time percentage would be 100%. If the 
blood glucose would be always more than 180 mg/dL 
for 24 hours, the percentage would be 0%.  
 
Results 
    The detailed profile of blood glucose variability was 
studied by FGM (Fig-1). On days 1 and 2, the meal 
was usual CR with 60% of carbohydrates. Average 
blood glucose was more than 300 mg/dL, and the 
time percentage of glucose level more than 180 mg/dL 
was 100% on days 1 and 2. From day 3, the meal 
changed into super-LCD with 12% of carbohydrates. 
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    Average blood glucose was gradually reduced, 
which was 235 mg/dL, 202 mg/dL, 228mg/dl, on day 
3,4,5, respectively. Time percentage of satisfactory 
blood glucose 70-180 mg/dL (/24h) was 0%, 0%, 2%, 
14%, 0% from day 1 to day 5, respectively.  
 
    On Day 6, the SGLT2 inhibitor was given in the 
early morning. Then, the blood glucose level was 
acutely reduced. Average blood glucose was 169 
mg/dL and 121 mg/dL on day 6 and 7. Time 
percentage of satisfactory blood glucose 70-180 
mg/dL (/24h) from day 6 and day 7 was 54% and 
100%, respectively (Fig-1). 
 
    On day 14, the diabetic biomarkers were 
remarkably improved. The value of HbA1c was 8.6%, 
        
Fig-1: Daily Profile of Blood Glucose by CGM (mg/dL) 
and glycoalbumin (GA) was 22.2%. 
 
Discussion 
    Historically speaking, the technical aspect of CGM 
was formerly reported by Updike et al. [19]. After 
that, some CGM experimental trials concerning the 
electrodes were observed [20]. There was the CGM 
guideline by the Clinical and Laboratory Standards 
Institute (CLSI) [21]. In addition, international 
standardization was presented such as mean absolute 
relative deviation (MARD) and precision absolute 
relative difference (PARD) [21,22]. 
 
    As for the clinical significance of CGM, the 
usefulness of the glucose variability was observed in  
patients with T2DM and other types [23]. 
Furthermore, the Food and Drug Administration 
(FDA) has recognized the management concerning the 
decisions of insulin dose from obtained CGM results 
[24].  
 
    CGM has been prevalent in diabetic practice as a 
useful apparatus in evaluating blood glucose 
variability and also artificial pancreas systems [25]. 
Successively, a real-time CGM (rtCGM) system was 
developed, which has been called flash glucose 
monitoring (FGM) [26]. Regarding the values of blood 
glucose, considerable agreements were observed 
between CGM and FGM, and then FGM has been 
applied to clinical practice with recent development 
[27]. As FGM reveals similarity to conventional CGM, 
there are some useful differences present in the case 
of FGM. One of the benefits is that the sensor has 
been factory calibrated without the necessity of 
calibration for blood glucose testing over 14-day. In 
addition, another benefit of FGM has been cheaper 
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than that of CGM [28]. On the other hand, it lacks the 
alarm mechanisms and connectivity in the case of 
continuous subcutaneous insulin infusion (CSII). 
Consequently, FGM has been highly evaluated to have 
usability and validated accuracy and usability in T1DM 
and T2DM [29].  
 
    In this report, we show the usability of FGM and 
the clinical effect of SGLT2 inhibitors have been 
introduced to the clinical practice, and they were 
proved to be a potent and effective agent for diabetes 
[30]. Since then, SGLT2 inhibitors have been 
evaluated to reveal clinical effects in various countries 
and then widely used [31]. Regarding their action, 
they inhibit renal reabsorption of glucose in the 
kidney. Consequently, blood sugar can be effectively 
reduced regardless of insulin activity [30,31].  
 
    Results of the randomized controlled trial (RCT) 
have been reported for the effectiveness of SGLT2 
inhibitors. As a result, HbA1c, fasting blood glucose 
and body weight have been reduced safely and 
effectively [32]. There is a recent study of the post-
marketing surveillance study of ipragliflozin. In this 
multi-center study, clinical efficacy was also 
confirmed [33]. 
 
    In the current study, the case showed the 
remarkable effect of SGLT2 inhibitor [34]. The case 
was provided a super-LCD meal on day 3,4,5. During 
three days, the blood glucose was moderately reduced 
compared with those in day 2. After that, the SGLT2 
inhibitor was administered on the morning of day 6. 
The profile of blood glucose showed an acute 
reduction from noon. This efficacy would be by the 
reduction of glucose toxicity that has been persisted 
for a long period. The definition of glucose toxicity 
means the impaired function of insulin secretion and 
sensitivity from persisting hyperglycemia [35]. SGLT2 
inhibitor has several mechanisms, such as increased 
urinary excretion of glucose and then decreased 
values of glucose profile [35]. 
 
    As for the measurement of urine sugar in the 
current case, the amount per day on day 3-5 was 
reduced as 47.7g, 17.2, 6.8 g/day. These data seemed 
to be the short-term effect of LCD. Successively, 52 g 
of urine sugar was observed on day 6. From these 
data, the SGLT2 inhibitor administration has brought 
the 45g difference of urinary sugar excretion between 
day 5 and day 6. Consequently, oral restriction of 
carbohydrate and urinary carbohydrate excretion 
would probably have a common pathophysiological 
mechanism.  
 
    From the pharmacological data of ipragliflozin, the 
amount of glucose excretion in urine was related to 
the renal function [34]. Daily excretion of glucose per 
day was reported to be about 71 g/day in normal 
subjects, 61g/day in rather mild renal impairment, 38 
g/day in moderate chronic renal disorder and 12g/day 
in severe chronic renal failure [36]. Then, these data 
suggest that the SGLT2 inhibitor would have a similar 
clinical effect to LCD meal for limiting the amount of 
carbohydrate 70g per day.  
 
    In this case, a large amount of sugar was excreted 
in the urine, and then the blood glucose level was 
decreased. As a result, the period of high 
hyperglycemia was significantly reduced from day 3 
to day 7. The activity of ipragliflozin is said to last 48 
hours [37]. The usual dose for adults is typically 50 
mg once a day and can be increased to 100 mg [38]. 
Based on the above, it is possible to adjust the dosing 
interval and dose amount depending on the situation 
of the patient [37].  
 
    From the pharmacological point of view, SGLT2 
inhibitors excrete high levels of sugar in the urine, 
and adverse effects include urinary tract infections 
and genital infections [39]. In our current study, FGM 
has shown that SGLT2 inhibitors may show an acute 
effect on the blood glucose  variability  associated  
with the consecutive urinary sugar excretion. 
Consequently, our data suggest that the 
administration of SGLT2 inhibitors could be 
investigated depending on the case in clinical settings. 
 
    In summary, T2DM patient was examined in the 
light of blood glucose variability with three situations. 
Those include meal intervention of CR, LCD, and LCD 
with an SGLT2 inhibitor. LCD showed the clinical 
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efficacy of lowering blood glucose. Furthermore, a 
remarkable lowering glucose effect was observed just 
after the administration of the SGLT 2 inhibitor. Our 
current report could be useful data for the 
administration of SGLT2 inhibitor depending on each 
case in future diabetic therapy. 
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